Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
GLP-1 (appetite) + GIP (insulin) + glucagon (energy burn) + amylin (fullness)
ideal performance range
What FDA Requires for NASH Approval FDA NASH Drug Approval Criteria (Based on Past Trials): Option 1: Histological Improvement (Biopsy-Based) NASH resolution (no inflammation, no ballooning) AND no worsening of fibrosis OR Fibrosis improvement (1 stage reduction) AND no worsening of NASH Option 2: Surrogate Endpoints (If Validated) Combination of imaging + biomarkers Must correlate with clinical outcomes Requires extensive validation Retatrutide's Current Status: Phase 2a: Fat reduction proven (surrogate endpoint) Phase 3 (TRIUMPH): Liver enzymes being measured (secondary) Still needs: Dedicated NASH trial with liver biopsies Phase 3 TRIUMPH: What Liver Data Will We Get
Its important to eat enough while breastfeeding to avoid reducing your supply
Well now explore the clinical trials and efficacy data supporting these findings
Andel is one of those partners
